## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 1.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. AstraZeneca: A Rare Compound Growth Opportunity In Biopharma (AZN)**
- Source: Seeking Alpha | 20251210T151143 | Bullish | Relevance: 99%
- AstraZeneca presents a unique growth opportunity in biopharma, driven by its diverse commercial assets and well-managed patent expiration profile. The company is set to launch 20 new molecular entities by 2030, aiming to almost double revenues to $80 billion, while facing only minor patent cliffs in the near term. With strong growth prospects, prudent R&D investment, and low leverage, AZN is rated as a "Buy" for long-term investors.

**2. Quantbot Technologies LP Reduces Stake in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251209T121010 | Somewhat-Bullish | Relevance: 99%
-  Quantbot Technologies LP significantly reduced its stake in AstraZeneca PLC by 72.9% in Q2 2025, selling 34,171 shares. Despite this, other institutional investors like Deutsche Bank AG increased their positions, and analysts maintain a "Moderate Buy" rating with a target price of $91.67 for AstraZeneca. The biopharmaceutical company recently surpassed EPS and revenue estimates, reporting $1.19 earnings per share and $15.19 billion in revenue for the quarter.

**3. AstraZeneca PLC ADR Rises Monday, Outperforms Market**
- Source: 富途牛牛 | 20251209T031010 | Bullish | Relevance: 97%
-  AstraZeneca's ADR rose on Monday, outperforming the broader market. This report also mentions Unity Software's Q4 earnings, which showed a revenue increase of 35% year-over-year to $609 million, surpassing analyst estimates, despite reporting a quarterly loss of 66 cents per share.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $280.0B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 17.5 |
| Current P/E | 19.7 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.9% to -0.9% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.91% (CS: 27) | Neutral |
| RSI_14 | 54.7 | Neutral |
| MACD Histogram | -0.35 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.176x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $90.29
- **Stop Loss:** $87.15 (3.5% risk)
- **Target:** $93.43 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 439
- **Position Value:** $39,637.31
- **Portfolio %:** 39.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*